Atara Biotherapeutics, Inc.
ATRA
$7.94
-$0.08-1.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 199.66% | -18.50% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 199.66% | -18.50% | |||
| Cost of Revenue | 11.28% | -31.07% | |||
| Gross Profit | 2,221.82% | 75.63% | |||
| SG&A Expenses | 6.05% | -9.41% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.18% | -27.43% | |||
| Operating Income | 498.39% | 43.91% | |||
| Income Before Tax | 399.01% | 42.02% | |||
| Income Tax Expenses | -- | -11.76% | |||
| Earnings from Continuing Operations | 399.46% | 42.06% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 399.46% | 42.06% | |||
| EBIT | 498.39% | 43.91% | |||
| EBITDA | 554.02% | 45.91% | |||
| EPS Basic | 397.94% | 59.61% | |||
| Normalized Basic EPS | 474.33% | 59.59% | |||
| EPS Diluted | 395.31% | 59.61% | |||
| Normalized Diluted EPS | 471.33% | 59.59% | |||
| Average Basic Shares Outstanding | 0.50% | 43.45% | |||
| Average Diluted Shares Outstanding | 1.32% | 43.45% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||